ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
Jack Cuzick
JACK CUZICK, Wolfson Institute of Preventive Medicine, London
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data
